These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1909485)

  • 61. Can we differentiate symptomatic and neuroprotective effects in parkinsonism? The dopamine agonist lisuride delays the need for levodopa therapy to a similar extent as reported for deprenyl.
    Runge I; Horowski R
    J Neural Transm Park Dis Dement Sect; 1991; 3(4):273-83. PubMed ID: 1772580
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Orally disintegrating selegiline in Parkinson patients with dopamine agonist-related adverse effects.
    Lyons KE; Friedman JH; Hermanowicz N; Isaacson SH; Hauser RA; Hersh BP; Silver DE; Tetrud JW; Elmer LW; Parashos SA; Struck LK; Lew MF; Pahwa R
    Clin Neuropharmacol; 2010; 33(1):5-10. PubMed ID: 19855267
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Slowing of information processing in Parkinson's disease.
    Revonsuo A; Portin R; Koivikko L; Rinne JO; Rinne UK
    Brain Cogn; 1993 Jan; 21(1):87-110. PubMed ID: 8424865
    [TBL] [Abstract][Full Text] [Related]  

  • 64. A study on the effect and tolerance of lisuride on Parkinson's disease.
    Bayülkem K; Erişir K; Tuncel A; Bayülkem B
    Adv Neurol; 1996; 69():519-30. PubMed ID: 8615174
    [TBL] [Abstract][Full Text] [Related]  

  • 65. One year treatment with lisuride delivery pump in Parkinson's disease.
    Ruggieri S; Stocchi F; Carta A; Bragoni M; Agostini C; Barbato L; Agnoli A
    Prog Neuropsychopharmacol Biol Psychiatry; 1989; 13(1-2):173-83. PubMed ID: 2748858
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Apomorphine and lisuride infusion. A comparative chronic study.
    Stocchi F; Bramante L; Monge A; Viselli F; Baronti F; Stefano E; Ruggieri S
    Adv Neurol; 1993; 60():653-5. PubMed ID: 8420205
    [No Abstract]   [Full Text] [Related]  

  • 67. Early selegiline therapy reduces levodopa dose requirement in Parkinson's disease.
    Myllylä VV; Heinonen EH; Vuorinen JA; Kilkku OI; Sotaniemi KA
    Acta Neurol Scand; 1995 Mar; 91(3):177-82. PubMed ID: 7793231
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Factors predictive of the need for levodopa therapy in early, untreated Parkinson's disease. The Parkinson Study Group.
    McDermott MP; Jankovic J; Carter J; Fahn S; Gauthier S; Goetz CG; Golbe LI; Koller W; Lang AE; Olanow CW
    Arch Neurol; 1995 Jun; 52(6):565-70. PubMed ID: 7763203
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Selegiline as the primary treatment of Parkinson's disease--a long-term double-blind study.
    Myllylä VV; Sotaniemi KA; Hakulinen P; Mäki-Ikola O; Heinonen EH
    Acta Neurol Scand; 1997 Apr; 95(4):211-8. PubMed ID: 9150811
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A dose-ranging study of selegiline in patients with Parkinson's disease: effect of platelet monoamine oxidase activity.
    Andreu N; Damase-Michel C; Senard JM; Rascol O; Montastruc JL
    Mov Disord; 1997 May; 12(3):293-6. PubMed ID: 9159721
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Selegiline delays the onset of disability in de novo parkinsonian patients. Swedish Parkinson Study Group.
    Pålhagen S; Heinonen EH; Hägglund J; Kaugesaar T; Kontants H; Mäki-Ikola O; Palm R; Turunen J
    Neurology; 1998 Aug; 51(2):520-5. PubMed ID: 9710028
    [TBL] [Abstract][Full Text] [Related]  

  • 72. The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study.
    Bracco F; Battaglia A; Chouza C; Dupont E; Gershanik O; Marti Masso JF; Montastruc JL;
    CNS Drugs; 2004; 18(11):733-46. PubMed ID: 15330687
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Continuous subcutaneous lisuride infusions in Parkinson's disease.
    Critchley PH; Grandas Perez F; Quinn NP; Parkes JD; Marsden CD
    J Neural Transm Suppl; 1988; 27():55-60. PubMed ID: 2969953
    [TBL] [Abstract][Full Text] [Related]  

  • 74. (-)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system.
    Knoll J
    J Am Geriatr Soc; 1992 Aug; 40(8):839-47. PubMed ID: 1634730
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.
    Brooks DJ; Sagar H;
    J Neurol Neurosurg Psychiatry; 2003 Aug; 74(8):1071-9. PubMed ID: 12876237
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Monamine oxidase inhibitors: current and emerging agents for Parkinson disease.
    Fernandez HH; Chen JJ
    Clin Neuropharmacol; 2007; 30(3):150-68. PubMed ID: 17545750
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Comparison of lisuride and bromocriptine in the treatment of advanced Parkinson's disease.
    Laihinen A; Rinne UK; Suchy I
    Acta Neurol Scand; 1992 Dec; 86(6):593-5. PubMed ID: 1481646
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Long-term persistence of symptomatic effect of selegiline in Parkinson's disease. A two-months placebo-controlled withdrawal study.
    Negrotti A; Bizzarri G; Calzetti S
    J Neural Transm (Vienna); 2001; 108(2):215-9. PubMed ID: 11314774
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Combination therapy of parkinsonism with deprenyl.
    Behari M; Ahuja GK; Singh K; Prasad K
    J Assoc Physicians India; 1992 Jun; 40(6):365-7. PubMed ID: 1452557
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Long-term observation of chronic subcutaneous administration of lisuride in the treatment of motor fluctuations in Parkinson's disease.
    Heinz A; Suchy I; Klewin I; Kuhn W; Klotz P; Przuntek H
    J Neural Transm Park Dis Dement Sect; 1992; 4():291-301. PubMed ID: 1388700
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.